Budding is useful to select high-risk patients in stage II well-differentiated or moderately differentiated colon adenocarcinoma

Diseases of the Colon and Rectum

Volumn 46, Issue 10, 2003, Pages 1400-1406

  Okuyama, Takashi ^a   Nakamura, Tetsuro ^b   Yamaguchi, Masahiko ^b  

^a DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Budding; Colon carcinoma; Prognosis; Stage II

Indexed keywords

EOSIN; HEMATOXYLIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CELL BUDDING; CELL DIFFERENTIATION; COLON ADENOCARCINOMA; COLON RESECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PROGNOSIS; STAINING; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 0142011608     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10350-004-6757-0     Document Type: Article

References (30)

1. Green FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, eds. American Joint Committee on Cancer staging manual. 6th ed. New York: Springer-Verlag, 2002.
2. Ducks CE. The classification of cancer of the rectum. J Pathol Bacteriol 1932;35:322-32.
3. Merkel S, Wein A, Gunther K, Papadopoulos T, Hohenberger W, Hermanek P. High-risk groups of patients with Stage II colon carcinoma. Cancer 2001;92:1435-43.
4. Imai T. The growth of human carcinoma. A morphological analysis [in Japanese]. Fukuoka Igaku Zasshi 1954;45:72-102.
5. Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie K, Morimatsu M. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 1989;63:539-43.
6. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 1993;36:627-35.
7. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumor "budding" as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002;40:127-32.
8. Umpleby HC, Ranson DL, Williamson RC. Peculiarities of mucinous colorectal carcinoma. Br J Surg 1985;72:715-8.
9. Minsky BD, Mies C, Rich TA, Recht A, Chaffey JT. Colloid carcinoma of the colon and rectum. Cancer 1987;60:3103-12.
10. Kanemitsu Y, Kato T, Hirai T, et al. Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis Colon Rectum 2003;46:160-7.
11. Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumors. Pathology and genetics of tumors of the digestive system. Lyon: IARC Press, 2000.
12. Astler VB, Coller FA. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954;139:846-52.
13. Minsky BD, Mies C, Rich TA, Recht A. Lymphatic vessel invasion is an independent prognostic factor for survival in colorectal cancer. Int J Radiat Oncol Biol Phys 1989;17:311-8.
14. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet 1987;2:1303-6.
15. Ueno H, Mochizuki H, Shinto E, Hashiguchi Y, Hase K, Talbot IC. Histologic indices in biopsy specimens for estimating the probability of extended local spread in patients with rectal carcinoma. Cancer 2002;94:2882-91.
16. Hase K, Shatney CH, Mochizuki H, et al. Long-term results of curative resection of "minimally invasive" colorectal cancer. Dis Colon Rectum 1995;38:19-26.
17. Okuyama T, Oya M, Ishikawa H. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma. Dis Colon Rectum 2002;45:628-34.
18. Jass JR, Barker M, Fraser L, et al. APC mutation and tumor budding in colorectal cancer. J Clin Pathol 2003;56:69-73.
19. Thebo JS, Senagore AJ, Reinhold DS, Stapleton SR. Molecular staging of colorectal cancer: k-ras mutation analysis of lymph nodes upstages Dukes B patients. Dis Colon Rectum 2000;43:155-62.
20. Purdie CA, Piris J. Histopathological grade, mucinous differentiation and DNA ploidy in relation to prognosis in colorectal carcinoma. Histopatholooy 2000;37:474-5.
21. Gervaz P, Bouzourence H, Cerottini J-P, et al. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 2001;44:364-73.
22. Burdy G, Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P. Identifying patients with T3-T4 nodenegative colon cancer at high risk of recurrence. Dis Colon Rectum 2001;44:1682-8.
23. Caplin S, Cerottini JP, Bosman FT, Constanda MT, Givel JC. For patients with Dukes' B (TNM stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer 1998;83:666-72.
24. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16:295-300.
25. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999;17:3553-9.
26. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999;17:1349-55.
27. Wolmark N, Rockett H, Wickerham DL, et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results from NSABP protocol C-02. J Clin Oncol 1990;8;1466-75.
28. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:1879-87.
29. Mamounas EP. Adjuvant chemotherapy for stage II colon cancer: the time has come. Eur J Surg Oncol 2000;26:725-9.
30. Wein A, Hahn EG, Merkel S, Hohenberger W. Adjuvant chemotherapy for stage II (Dukes' B) colon cancer: too early for routine use. Eur J Surg Oncol 2000;26:730-2.